



2023 AASLD Abstract Categories and Descriptors (The Liver Meeting®)

Acute Liver Failure and Artificial Liver Support

AO1 Acute Liver Failure and Artificial Liver Support

Acute on Chronic Liver Failure

BO1 Acute on Chronic Liver Failure

Advanced Practice Providers (NP, PA, RN, PharmD, etc.)

CO1 Behavioral and Quality Issues

CO2 Practice Issues

Alcohol-associated Liver Diseases: Clinical and Experimental

DO1 Alcohol-associated Liver Diseases: Clinical and Experimental

Biliary Physiology, Transport, Cholangiocyte Biology, and Experimental Cholestasis

EO1 Transport, Bilirubin, Cholesterol, Lipids, and Bile Salts

EO2 Cholangiocyte Biology

EO3 Experimental Cholestasis

Cell and Molecular Biology

FO1 Cell Structure and Function

FO2 Signal Transduction and Nuclear Receptors

FO3 Gene Expression and Therapy

FO4 Stem Cell Biology

Genomics and Precision Medicine

GO1 Genomics and Precision Medicine

Gut Liver Axis and Microbiome

HO1 Gut Liver Axis and Microbiome

Health Disparities/Health Equity Research

(includes health disparities affecting minoritized groups by race, ethnicity gender, LGTQ+ status, geography, and socioeconomic status)

IO1 Social Determinants of Health

IO2 Special Populations

Health Services and Public Health Research

JO1 Health Care Delivery/Access/Quality

JO2 Cost-Effectiveness and Economics of Care

JO3 Patient Centered Outcomes Research

Hepatitis B

KO1 Virology, Pathogenesis, and Immunology

KO2 Diagnostics and Biomarkers

KO3 Epidemiology, Prevention, Natural History

KO4 Therapeutics: Approved Agents

KO5 Therapeutics: New Agents



Hepatitis C

- LO1 Virology, Pathogenesis, and Immunology
- LO2 Diagnostics and Biomarkers
- LO3 Epidemiology, Prevention, Natural History
- LO4 Therapeutics: Approved and New Agents

Hepatitis: Other Infections

- MO1 Hepatitis: Other Infections

Hepatobiliary Neoplasia

- NO1 Experimental Hepatocarcinogenesis
- NO2 Diagnostics and Liver Imaging
- NO3 Clinical: Hepatocellular Carcinoma and Cholangiocarcinoma

Hepatotoxicity

- OO1 Pathogenesis and Mechanisms
- OO2 Drug Metabolism, Toxicity and Therapeutics
- OO3 Predictors of Drug Toxicity

Human Cholestatic and Autoimmune Liver Diseases

- PO1 PBC/PSC and Other Cholestatic Disease
- PO2 Autoimmune Liver Disease

Inflammation and Immunobiology

- QO1 Animal Models
- QO2 Innate Immunity
- QO3 Adaptive Immunity
- QO4 Mechanisms of Injury

Liver Fibrogenesis and Non-Parenchymal Cell Biology

- RO1 Basic Fibrosis Research and Stellate Cell Biology
- RO2 Kupffer Cell Biology
- RO3 Imaging and Noninvasive Markers of Liver Disease
- RO4 Clinical and Translational Fibrosis Research

Liver Transplantation and Liver Surgery

- SO1 Cellular Immunobiology, Preservation, and Cell Transplantation
- SO2 Donor and Allocation Issues, Living Donor and Split Liver Transplantation, and Hepatobiliary Surgery
- SO3 Immunosuppression, Outcomes, Complications
- SO4 Prevention and Treatment of Recurrent Disease

Metabolic and Genetic Disease

- TO1 Hemochromatosis, Wilson Disease, and α -1 Antitrypsin Deficiency

MASLD and MASH

- UO1 Experimental: Basic
- UO2 Experimental: Clinical
- UO3 Epidemiology and Natural History, Prevention and Outcomes
- UO4 Diagnostics and Biomarkers
- UO5 Treatment: Non-pharmacologic
- UO6 Therapeutics: Approved/Available Agents
- UO7 Therapeutics: New Agents



Pediatric Hepatology

- VO1 Pediatric Liver Disease – Basic Science
- VO2 Biliary Atresia and Neonatal Cholestasis
- VO3 Viral and Autoimmune Liver Disease
- VO4 Metabolic and Genetic Diseases
- VO5 Pediatric Liver Transplantation

Portal Hypertension and Other Complications of Cirrhosis

- WO1 Experimental
- WO2 Ascites, Renal Dysfunction, and Hepatorenal Syndrome
- WO3 Varices and Bleeding
- WO4 Encephalopathy, Infections and Other Complications

Vascular Liver Disease, Hemostasis and Thrombosis

- XO1 Vascular Liver Disease
- XO2 Hemostasis and Thrombosis
- XO3 Liver Sinusoidal Endothelial Cells